非小细胞肺癌中DPC4、VEGF基因的表达及相关性研究

目的:研究DPC4和VEGF基因在非小细胞肺癌中的表达及相关性.方法:利用免疫组织化学SP法检测60例NSCLC组织、10例相应的癌旁正常肺组织中DPC4、VEGF的表达.结果:DPC4在60例NSCLC标本中的阳性表达率为63.3%(38/60),癌旁正常肺组织中的阳性表达率90.0%(9/10),差别有显著性意义(P＜0.05);DPCA与患者的年龄、性别、组织学类型、TNM分期、肿瘤细胞分化程度无关(P＞0.05),而与淋巴结转移显著相关(P＜0.05).肺癌组织中VEGF阳性率(81.7%,49/60)明显高于正常肺组织(20.0%,2/10),有显著性差别(P＜0.05);VEGF的阳性表达与患者的年龄、性别、组织学类型无关(P＞0.05),而与TNM分期、肿瘤细胞分化程度、淋巴结转移明显相关.60例NSCLC中,DPCA的表达与VEGF呈明显的负相关(r=0.303,P＜0.05).结论:DPC4在肺癌组织中低表达,可促进肺癌的淋巴结转移.VEGF在肺癌组织中高表达,可促进肺癌的发生、发展、转移.DPC4、VEGF在肺癌中的表达呈负相关,提示DPC4可能通过下调VEGF的表达而抑制血管的生成.     

The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung

Introduction

While some targeted agents should not be used in squamous cell carcinomas (SCCs), other agents might preferably target SCCs. In a previous microarray study, one of the top differentially expressed genes between adenocarcinomas (ACs) and SCCs is P63. It is a well-known marker of squamous differentiation, but surprisingly, its expression is not widely used for this purpose. Our goals in this study were (1) to further confirm our microarray data, (2) to analize the value of P63 immunohistochemistry (IHC) in reducing the number of large cell carcinoma (LCC) diagnoses in surgical specimens, and (3) to investigate the potential of P63 IHC to minimize the proportion of “carcinoma NOS (not otherwise specified)” in a prospective series of small tumor samples.

Methods

With these goals in mind, we studied (1) a tissue-microarray comprising 33 ACs and 99 SCCs on which we performed P63 IHC, (2) a series of 20 surgically resected LCCs studied for P63 and TTF-1 IHC, and (3) a prospective cohort of 66 small thoracic samples, including 32 carcinoma NOS, that were further classified by the result of P63 and TTF-1 IHC.

Results

The results in the three independent cohorts were as follows: (1) P63 IHC was differentially expressed in SCCs when compared to ACs (p<0.0001); (2) half of the 20 (50%) LCCs were positive for P63 and were reclassified as SCCs; and (3) all P63 positive cases (34%) were diagnosed as SCCs.

Conclusions

P63 IHC is useful for the identification of lung SCCs.     

肿瘤靶向治疗在NSCLC中的应用

肺癌已成为21世纪威胁人类健康最主要原因之一,全球每年因非小细胞肺癌(NSCLC)死亡的人数超过100万人.传统的抗肿瘤药物极大改善了NSCLC患者的预后.由于缺乏选择性和很强的细胞毒性,多中心研究表明化疗方案疗效已经达到治疗平台,应致力于研发作用机制不同于化疗的药物.肿瘤靶向治疗通过针对特异性的靶点来杀死和抑制肿瘤细胞,避免了对正常细胞的伤害,已成为当前肿瘤研究的热点,并已在临床肿瘤治疗中取得了一定疗效.随着肿瘤分子生物学与细胞生物学的发展,人们对肺癌癌变、侵袭转移的分子机理以及生物信号传导通路的认识加深,新的靶向治疗药物不断出现.本文就近年靶向治疗技术的进展及分子靶向药物在NSCLC中的应用作一综述.     

miR-32在非小细胞肺癌中的表达

目的:基于芯片数据库分析的基础上,探讨miR-32在非小细胞肺癌患者中的表达水平。方法:在GEO和Array Expression数据库中搜索关键词"microRNA和肺癌"检索出两个样本量最大的芯片数据,分别是GEO数据库中编码为GSE61741和Array Expression数据库中编码为E-TABM-22的芯片数据,对两组数据进行分析找出有差异的microRNA。另外收集2010.02-2012.09期间在吉林大学附属中日联谊医院胸外科进行肺癌手术切除的32名患者的肺癌组织及配对的癌旁正常肺组织标本,检测标本中miR-32的表达水平。结果:综合分析GSE61741和E-TABM-22的芯片数据发现有共同差异的microRNA共有8个,其中上调的有2个,分别是hsa-miR-192与hsa-miR-197,下调的有6个,分别是hsa-miR-126、hsa-miR-199b-3p、hsa-miR-219-1-3p、hsa-miR-26a、hsa-miR-32与hsa-miR-9。为了进一步探讨miR-32在癌症中的作用,我们对GSE61741中其他癌症患者及健康者血浆中miR-32的芯片数据进行分析,发现miR-32在结肠癌、神经胶质瘤、肾癌、前列腺癌、Wilm's瘤中的表达水平均显著低于健康者(P0.01)。对32例及E-TABM-22芯片数据中65例NSCLC患者癌及配对的癌旁正常肺组织中miR-32的表达水平分析发现癌组织中miR-32的表达水平显著下调(P0.001)。结论:miR-32在非小细胞肺癌组织中低表达,提示miR-32可能为新的NSCLC诊断标记分子。     

Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer

Cisplatin, a platinum-based chemotherapeutic drug, has been used for over 30 years in a wide variety of cancers with varying degrees of success. In particular, cisplatin has been used to treat late stage non-small cell lung cancer （NSCLC） as the standard of care. However, therapeutic outcomes vary from patient to patient. Considerable efforts have been invested to identify biomark- ers that can be used to predict cisplatin sensitivity in NSCLC. Here we reviewed current evidence for cisplatin sensitivity biomarkers in NSCLC. We focused on several key pathways, including nucleotide excision repair, drug transport and metabolism. Both expression and germline DNA variation were evaluated in these key pathways. Current evidence suggests that cisplatin-based treatment could be improved by the use of these biomarkers.     

Phosphosignature Predicts Dasatinib Response in Non-small Cell Lung Cancer

Targeted drugs are less toxic than traditional chemotherapeutic therapies; however, the proportion of patients that benefit from these drugs is often smaller. A marker that confidently predicts patient response to a specific therapy would allow an individual therapy selection most likely to benefit the patient. Here, we used quantitative mass spectrometry to globally profile the basal phosphoproteome of a panel of non-small cell lung cancer cell lines. The effect of the kinase inhibitor dasatinib on cellular growth was tested against the same panel. From the phosphoproteome profiles, we identified 58 phosphorylation sites, which consistently differ between sensitive and resistant cell lines. Many of the corresponding proteins are involved in cell adhesion and cytoskeleton organization. We showed that a signature of only 12 phosphorylation sites is sufficient to accurately predict dasatinib sensitivity. Four of the phosphorylation sites belong to integrin β4, a protein that mediates cell-matrix or cell-cell adhesion. The signature was validated in cross-validation and label switch experiments and in six independently profiled breast cancer cell lines. The study supports that the phosphorylation of integrin β4, as well as eight further proteins comprising the signature, are candidate biomarkers for predicting response to dasatinib in solid tumors. Furthermore, our results show that identifying predictive phosphorylation signatures from global, quantitative phosphoproteomic data is possible and can open a new path to discovering molecular markers for response prediction.     

非小细胞肺癌免疫治疗的研究进展

肺癌(lung cancer)是全球发病率及死亡率最高的恶性肿瘤之一,非小细胞肺癌(non-small cell lung cancer,NSCLC)占肺癌的85%,其五年生存率只有15%,传统的抗肿瘤治疗方法(手术、放疗和化疗等)在抑制肿瘤进展中的作用有限,即使有手术机会,也有40%以上患者出现局部复发或远处转移。目前多学科治疗较大程度提高了晚期NSCLC的生存期,研究表明,免疫治疗(immunotherapy)可改善肺癌的预后,有望成为肺癌的重要辅助治疗方式。其中,治疗性肿瘤疫苗(vaccination)如MAGE-A3、L-BLP25、Belagenpum atucel-L等、免疫检查点抑制剂(immune checkpoint inhibition)如ipilimumab、nivolumab、pembrolizumab等得到广泛关注。一系列临床试验表明免疫治疗可以使非小细胞肺癌的死亡率得到缓解,本文就其原理、临床试验、不良反应及有待解决问题的临床研究作系统综述。     

Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation

Lung cancer represents the leading cause of cancer-related deaths in men and women worldwide. Targeted therapeutics, including the epidermal growth factor receptor (EGFR) inhibitor erlotinib, have recently emerged as clinical alternatives for the treatment of non-small cell lung cancer (NSCLC). However, the development of therapeutic resistance is a major challenge, resulting in low 5-year survival rates. Due to their ability to act as tumor suppressors, microRNAs (miRNAs) are attractive candidates as adjuvant therapeutics for the treatment of NSCLC. In this study, we examine the ability of 2 tumor suppressor miRNAs, let-7b and miR-34a to sensitize KRAS;TP53 mutant non-small cell lung cancer cells to the action of erlotinib. Treatment with these miRNAs, individually or in combination, resulted in synergistic potentiation of the anti-proliferative effects of erlotinib. This effect was observed over a wide range of miRNA and erlotinib interactions, suggesting that let-7b and miR-34a target oncogenic pathways beyond those inhibited by EGFR. Combinatorial treatment with let-7b and miR-34a resulted in the strongest synergy with erlotinib, indicating that these miRNAs can effectively target multiple cellular pathways involved in cancer cell proliferation and resistance to erlotinib. Together, our findings indicate that NSCLC cells can be effectively sensitized to erlotinib by supplementation with tumor suppressor miRNAs, and suggest that the use of combinations of miRNAs as adjuvant therapeutics for the treatment of lung cancer is a viable clinical strategy.     

扣除杂交法筛选与非小细胞性肺癌转移相关的基因

非小细胞性肺癌病人的术后死亡率很高 ,其原因是该病易发生转移。收集了肺癌早期患者的样品 ,并根据患者资料分成转移型 (n =4)和非转移型 (n =5 ) ,采用扣除杂交法筛选与非小细胞性肺癌转移相关的基因。扣除后的cDNA文库中得到了 2 2 5个有效克隆。对这些克隆进行了测序 ,在基因文库中比较了核苷酸同源性 ,初步确定了这些克隆对应的基因 ,并根据基因可能涉及的功能加以分类。通过实时 (realtime)RT PCR鉴定 ,发现 10种基因在用于扣除试验的转移病人样品中的平均表达量比非转移病人高。进一步对 70位患非小细胞性肺癌病人 (I至IIIA期 )的样品进行了检测。根据统计分析 ,在I和II期病人中 ,2种基因MALA1和EIF4A1在发生转移的病人样品中的表达与在非转移的病人中有显著差异性。这些结果将有助于分析非小细胞性肺癌病变发生转移的可能性     

Angiogenesis measured by expression of CD34 antigen in lymph nodes of patients with non-Hodgkin's lymphoma

Angiogenesis is important in development, maintenance and progression of haematological malignancies. Some clinical observations have indicated that in non-Hodgkin's lymphoma (nHL) tumour microvessel density (MVD) may correlate with tumour staging and outcome. The aim of the study was to examine relationship between MVD as a parameter of tumour angiogenesis measured by expression of CD34 and the grade of nHL histological malignancy as determined by REAL classification. 40 lymph node samples of patients with newly diagnosed nHL (17 women, 23 men; aged 48-70 yrs, median age 64 yrs; stage III and IV) and treated at the Department of Haematology, Wroc?aw Medical University in 1999-2002 were fixed in 10% buffered formalin and embedded in paraffin. In all the studied cases, sections were incubated with antibodies against CD34. The slides were stained with hematoxylin and eosin and evaluated histopathologically. Patients were divided into two groups according to histological malignancy: indolent nHL (19 patients) and aggressive nHL (21 patients). Mean MVD measured by expression of CD34 in aggressive and indolent nHL groups amounted to 19.45 +/- 11.24 vessels/0.375 mm2 and 21.7 +/- 12.4 vessels/0.375 mm2, respectively. Statistical analysis of microvessel staining demonstrated no correlation between tumour MVD and grade of histological malignancy in lymph nodes of nHL patients. Nevertheless, angiogenesis observed in nHL provides rationale for use of angiogenesis inhibitors in lymphoma therapy.     

化疗在中晚期非小细胞肺癌患者中对淋巴细胞亚群影响分析

目的:探讨化疗在中晚期非小细胞肺癌患者中对淋巴细胞亚群的影响。方法:随机抽取本院收治的60例中晚期非小细胞肺癌患者编为实验组进行化疗,另选取同期体检的50例健康志愿者作为对照组。随访12月-15月,采用流式细胞仪技术分别对两组外周血淋巴细胞亚群进行检测计数。结果:两组间相比,实验组患者的CD3+、CD4+、NK细胞的数量以及CD4+/CD8+比值均低于对照组(P<0.05),而CD8+细胞的比例却高于对照组。化疗后CD3+、CD4+、CD4+/CD8+、NK均较化疗前升高(P<0.05),但CD8+不变(P>0.05)。结论:应用化疗治疗中晚期非小细胞肺癌,可明显改善患者的免疫功能。     

非小细胞肺癌低分割放疗研究进展

肺癌是全球发病率和死亡率第一的恶性肿瘤,虽然放疗在NSCLC的治疗中具有可观的局部疗效,但临床上仍有部分患者出现治疗失败。放疗失败的主要原因是局部未控、复发或远处转移。与常规分割相比,大分割放疗可在不增加放疗次数的情况下提高总的放疗剂量;对于接受相同BED照射的NSCLC患者,大分割放疗除了能带来局部控制率上的增加外,还可减少治疗次数,节省治疗时间和费用,增加病人的便捷,提高医用加速器的使用效率。L-Q模型的数据在预测大分割放疗疗效时存在许多局限。除经典L-Q模型所模拟的机制外,还可能有其他机制的参与。分子影像是无创性评价放疗疗效的可靠手段,利用不同分子显像剂结合胞内特定靶分子,能够对恶性肿瘤的代谢水平、乏氧状态、增殖能力等情况进行较为准确的评估,为大分割放疗提供良好的疗效评估手段并成为研究其特殊放射生物效应的有力工具。     

MicroRNA-34a通过多向调控促癌基因抑制肾癌细胞生长

目的:探讨microRNA-34a(miR-34a)在肾癌细胞中的生物学作用及调控机制.方法:应用miR-34amimics在体外转染769P,786-O和Caki-1细胞;运用qRT-PCR检测miR-34a在三个细胞株的相对表达情况,以及转染后癌基因mRNA的表达情况;观察miR-34a对细胞生长的影响.结果:769P,786-O和Caki-1细胞中miR-34a在786-O中表达最低,769P次之,Caki-1表达最高;利用miR-34a mimics升高769P,786-O和Caki-1细胞miR-34a,发现三个细胞株多个癌基因mRNA表达不同程度的降低(P＜0.05)及生长和集聚能力的降低.结论:miR-34a可能通过调控多个癌基因表达在肾癌中起抑癌作用.miR-34a mimics可抑制肾癌细胞的生长,因此miR-34a有可能作为肾癌基因治疗的新靶点.     

miR-29a靶向调控PDGFB促进非小细胞肺癌细胞凋亡

为了探究miR-29a对非小细胞肺癌细胞增殖和凋亡的影响及分子机制,本研究通过荧光定量PCR检测肺癌组织、癌旁组织、肺癌细胞以及人正常肺支气管上皮细胞BEAS-2B中miR-29a的表达,在肺癌A549转染miR-29a mimics后,使用荧光定量PCR和CCK-8法分别检测miR-29a的表达以及各组细胞的活力,使用流式细胞术检测A549细胞凋亡;通过荧光定量PCR检测肺癌组织、癌旁组织PDGFB m RNA的表达,采用Western blot检测PDGFB蛋白的表达;使用双荧光素酶报告基因检测miR-29a可能的靶基因;在肺癌A549细胞转染miR-29a mimics后继续转染PDGFB过表达质粒,通过qPCR和Western blotting分别检测PDGFB mRNA和蛋白的表达。结果表明,与癌旁组织相比,miR-29a在肺癌组织的表达显著下调(p<0.01),PDGFB在肺癌组织的表达显著增加(p<0.01);转染miR-29a mimics后,肺癌A549细胞中miR-29a表达显著增加(p<0.01);CCK-8法结果显示miR-29a mimics组A549肺癌细胞在24 h和48 h后细胞增值率较miR-NC对照组显著降低(p<0.01);流式细胞术结果显示miR-29a mimics组的细胞凋亡率较miR-NC对照组显著增加(p<0.01);与miR-NC+PDGFB 3’UTR WT组相比,miR-29a mimics+PDGFB 3’UTR WT组的荧光强度显著降低(p<0.01);荧光定量PCR和Western blotting显示miR-29a mimics+PDGFB组PDGFB m RNA和蛋白表达量与miR-29a mimics+vector组相比显著增加(p<0.01)。本研究结果表明miR-29a在肺癌组织和肺癌细胞株中低表达,及抑制PDGFB的表达并且促进肺癌细胞凋亡。     

丝甘蛋白聚糖促进非小细胞肺癌的侵袭与转移

丝甘蛋白聚糖(serglycin,SRGN)在肿瘤细胞的侵袭与转移中具有广泛的研究前景。本研究报道SRGN与肺癌细胞侵袭与转移能力之间的相关性。首先,通过检测SRGN在正常肺上皮细胞株BEAS-2B及不同侵袭与转移能力的肺癌细胞株95C、95D中的表达差异。利用shRNA干扰技术,在侵袭与转移能力强的95D细胞中建立稳定干扰SRGN表达的95D/shSRGN的细胞株,并通过RT-qPCR、Western印迹、酶联免疫吸附测定验证其敲除效率。结果显示：干扰SRGN可抑制侵袭与转移性强的95D细胞的侵袭与转移能力,减弱细胞迁移与侵袭等生物学特性,导致上皮标志物上皮细胞钙黏连蛋白（E-cadherin）表达上调,间质标志物纤维连接蛋白1（fibronectin1, FN1）及EMT（epithelial-mesenchymal transition, EMT）相关转录因子锌指E盒结合同源框1（zinc finger E-box binding homeobox 1, ZEB1）表达下调。进一步分析发现, SRGN与上皮细胞钙黏连蛋白表达成负相关（P=-0.25）,而与FN1(P=0.12)及ZEB1(P=0.35)表达成正相关,并且SRGN高表达的患者总生存时间明显少于SRGN低表达组（P=0.0077）,SRGN与ZEB1同时高表达的患者,总生存时间显著小于SRGN与ZEB1低表达患者（P=0.0005）。研究结果证实,SRGN促进上皮间质转化发生,增强非小细胞肺癌的侵袭与转移能力,为非小细胞肺癌预后提供参考。     

Rhamnetin and Cirsiliol Induce Radiosensitization and Inhibition of Epithelial-Mesenchymal Transition (EMT) by miR-34a-mediated Suppression of Notch-1 Expression in Non-small Cell Lung Cancer Cell Lines

Radioresistance is a major cause of decreasing the efficiency of radiotherapy for non-small cell lung cancer (NSCLC). To understand the radioresistance mechanisms in NSCLC, we focused on the radiation-induced Notch-1 signaling pathway involved in critical cell fate decisions by modulating cell proliferation. In this study, we investigated the use of Notch-1-regulating flavonoid compounds as novel therapeutic drugs to regulate radiosensitivity in NSCLC cells, NCI-H1299 and NCI-H460, with different levels of radioresistance. Rhamnetin and cirsiliol were selected as candidate Notch-1-regulating radiosensitizers based on the results of assay screening for activity and pharmacological properties. Treatment with rhamnetin or cirsiliol reduced the proliferation of NSCLC cells through the suppression of radiation-induced Notch-1 expression. Indeed, rhamnetin and cirsiliol increased the expression of tumor-suppressive microRNA, miR-34a, in a p53-dependent manner, leading to inhibition of Notch-1 expression. Consequently, reduced Notch-1 expression promoted apoptosis through significant down-regulation of the nuclear factor-κB pathway, resulting in a radiosensitizing effect on NSCLC cells. Irradiation-induced epithelial-mesenchymal transition was also notably attenuated in the presence of rhamnetin and cirsiliol. Moreover, an in vivo xenograft mouse model confirmed the radiosensitizing and epithelial-mesenchymal transition inhibition effects of rhamnetin and cirsiliol we observed in vitro. In these mice, tumor volume was significantly reduced by combinational treatment with irradiation and rhamnetin or cirsiliol compared with irradiation alone. Taken together, our findings provided evidence that rhamnetin and cirsiliol can act as promising radiosensitizers that enhance the radiotherapeutic efficacy by inhibiting radiation-induced Notch-1 signaling associated with radioresistance possibly via miR-34a-mediated pathways.     

miR-182靶向抑制FBXW7表达影响非小细胞肺癌细胞增殖研究

目的:研究microRNA-182(miR-182)在非小细胞肺癌(NSCLC)组织中的表达,并探讨其对NSCLC细胞增殖的影响及作用机制。方法:采用实时荧光定量PCR (qRT-PCR)检测miR-182在11例NSCLC及相应癌旁组织中的表达情况;Western blot检测FBXW7,c-Jun,c-Myc及cyclin D蛋白的表达;将miR-182模拟物,抑制物及相应空白对照瞬时转染H460细胞后,以细胞增殖与活性检测和克隆形成实验检测细胞系的增殖情况;流式细胞术检测细胞周期和凋亡变化;荧光素酶报告基因实验证实miR-182对FBXW7的靶向性作用。结果:NSCLC组织中miR-182的相对表达水平显著高于癌旁组织(P0.05)。转染组与对照组相比,H460细胞生长、克隆形成能力显著增强,细胞周期进程加快,细胞凋亡受到抑制(P0.05)。在NSCLC组织中,FBXW7蛋白的表达水平明显低于癌旁组织(P0.05)。miR-182 mimics显著降低野生型FBXW7质粒荧光素酶的活性,然而将结合位点突变后,miR-182 mimics则不再影响荧光素酶的活性。结论:miR-182在NSCLC组织中高表达,与FBXW7之间存在靶向关系,通过下调FBXW7蛋白表达促进NSCLC细胞的增殖,参与肿瘤的发生发展,预示其可能成为一种潜在的生物标志和治疗靶点。     

Inhibition of Proliferation of Non-small Cell Lung Cancer Cells by a bFGF Antagonist Peptide

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. Basic fibroblast growth factor (bFGF) is up-regulated in NSCLC patients and plays an important role in tumor growth. In this paper, we attempt to evaluate the therapeutic potential of bFGF binding peptide (named as P7) using as a potent bFGF antagonist via exploration of its anti-proliferation effect on NSCLC cells. Our experiments showed that P7 peptide inhibited bFGF-stimulated proliferation of NSCLC cell lines including A549, H1299, and H460. The inhibitory mechanism of P7 involved cell cycle arrest at the G0/G1phase caused by suppression of cyclin D1, blockage of the activation of Erk1/2, P38, Akt, and inhibition of bFGF internalization. Strategies using bFGF antagonist peptides with potent anti-proliferation property may have therapeutic potential in NSCLC.     

非小细胞肺癌的免疫治疗进展

肺癌是最致命的恶性肿瘤之一,也是男性肿瘤患者致死率最高的,5年生存率低于18%。尽管非小细胞肺癌(non-small cell lung cancer,NSCLC)在手术治疗、化疗、放疗以及靶向治疗方面均取得了一定的成果,但晚期NSCLC的预后依然很差。免疫治疗为NSCLC患者提供了一个新的治疗方向。免疫治疗目前主要研究方向在免疫检查点抑制剂(Ipilimumab、Nivolumab、MK-3475)和肿瘤疫苗(MAGE-A3,L-BLP25,TG4010,Belagenpumatucel-L)等。免疫治疗具有针对性强、副作用少、效率高的特点,并在Ⅱ、Ⅲ期临床试验中取得了较好的疗效,成为在手术、化疗、放疗以及靶向治疗后一种新的重要治疗手段。本文就当前非小细胞肺癌免疫治疗原理、临床试验及待解决问题作一综述。     

RHCG基因在非小细胞肺癌中的表达及对细胞增殖的影响

为了探讨Rh type C glycoprotein (RHCG)对非小细胞肺癌(non-small cell lung cancer,NSCLC)细胞增殖的影响及可能的作用机制,本研究使用荧光定量PCR法检测12对NSCLC及癌旁组织样本中RHCG mRNA的表达水平及pcDNA3.1-RHCG质粒对A549细胞RHCG m RNA的表达;采用CCK-8法检测细胞增殖能力;运用PI染色法检测细胞周期;使用免疫印迹法检p-PI3K、PI3K、p-AKT以及AKT蛋白表达水平。本研究发现,与癌旁组织比较,NSCLC中RHCG m RNA表达水平明显降低。RHCG过表达能抑制NSCLC细胞系A549细胞增殖能力。此外,RHCG过表达使A549细胞周期G1/S期转化发生阻滞。本研究还发现,RHCG过表达可下调A549细胞p-PI3K/PI3K和p-AKT/AKT水平。本研究表明,RHCG抑制NSCLC细胞增殖的作用与其抑制PI3K/AKT信号通路有关。